title: Tear trough rejuvenation: A safety evaluation of the treatment by a semi-cross-linked hyaluronic acid filler.
abstract: The aim of this study is to describe the experience of 33 physicians, dermatologists and surgeons, with the use of a semi-cross-linked hyaluronic acid (HA) gel as a tear trough deformity filler within one month following injection, and to assess patient satisfaction with the procedure. This study is a case series conducted between February 2012 and December 2012 with the use of semi-cross-linked HA to correct tear trough deformity. The filler was administered in the preperiosteal tissues. The study involved case note review and a patient satisfaction survey. A total of 302 eyes of 151 patients were treated by 33 physicians, with a mean follow-up of 3 weeks. Patients were mainly female (86%), and middle-aged (mean age 48 years old). The gel was placed preperiosteally, deep to the orbicularis, anterior to the inferior orbital rim, with a mean volume of 0.48 ml per eye to achieve correction. The injection procedure was performed without local anesthetic for 79% of the patients. No serious adverse event was recorded. Side effects reported by investigators immediately after injection included bruising (11%), swelling (12%), and redness (inflammation 12%). Very few transitional blue discolorations (2.6%) were observed. No patient required dissolution with hyaluronidase. According to our satisfaction survey, all patients had cosmetic improvement. Most patients (97%) described marked or moderate satisfaction with the treatment. At one month, 18% requested additional hyaluronic acid gel for a touch-up injection. This case series confirms the effective use of a semi-cross-linked HA gel in tear trough rejuvenation. It has excellent patient tolerability, minimal complications, and excellent patient satisfaction.
authors.affiliation: a Department of Oculoplastic Surgery , Fondation Rothschild , Paris , France.
authors.forename: Marouen
authors.initials: M
authors.lastname: Berguiga
authors.affiliation: a Department of Oculoplastic Surgery , Fondation Rothschild , Paris , France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Galatoire
mesh_terms: D003357:Cosmetic Techniques; D000067548:Dermal Fillers / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D007279:Injections, Subcutaneous; D007765:Lacrimal Apparatus / Q000187:drug effects*; D008297:Male; D057748:Mesotherapy; D008875:Middle Aged; D017060:Patient Satisfaction / Q000706:statistics & numerical data; D011446:Prospective Studies; D012060:Rejuvenation; D015595:Skin Aging / Q000187:drug effects*; D055675:Viscosupplements / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000067548:Dermal Fillers; C560018:Teosyal 27G Deep Lines; D055675:Viscosupplements; D006820:Hyaluronic Acid
keywords: Cosmetic medicine; hollow ring; hyaluronic acid fillers; non-invasive facial rejuvenation; tear trough